Skip to search formSkip to main contentSkip to account menu

AMG 330

Known as: Bispecific T-cell Engager Antibody AMG 330, AMG330, Anti-CD33/CD3 BiTE Antibody AMG 330 
A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Antibodies, Bispecific
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Background: Current treatment options for R/R AML are highly inadequate. CD33 is expressed in >99% of AML cases. BiTE®s have… 
Highly Cited
2016
Highly Cited
2016
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
Bispecific T-cell engagers (BiTEs) are very effective in recruiting and activating T cells. We tested the cytotoxicity of the… 
Highly Cited
2014
Highly Cited
2014
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
Antibody-based immunotherapy represents a promising strategy to target and eliminate chemoresistant leukemic cells. Here, we… 
Highly Cited
2014
Highly Cited
2014
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
CD33 is a valid target for acute myeloid leukemia (AML) but has proven challenging for antibody-drug conjugates. Herein, we… 
Highly Cited
2014
Highly Cited
2014
Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
There is high demand for novel therapeutic options for patients with acute myelogenous leukemia (AML). One possible approach is… 
Highly Cited
2012
Highly Cited
2012
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
For treatment of patients with prostate cancer (PCa), we developed a novel T cell-engaging (BiTE) antibody designated AMG 212 or… 
Highly Cited
2009
Highly Cited
2009
Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption.
Supersaturatable self-emulsifying drug delivery systems (S-SEDDS) were explored to improve the oral absorption of AMG 517, a… 
Highly Cited
1998
Highly Cited
1998
A comparative study on different methods of automatic mesh generation of human femurs.
Highly Cited
1989
Highly Cited
1989
1-O-hexadecyl-2-Q-methylglycerol, a novel inhibitor of protein kinase C, inhibits the respiratory burst in human neutrophils.
Highly Cited
1975
Highly Cited
1975
Quantitative degradation of chlorophyll by a marine herbivore1
In laboratory grazing experiments, primarily with Calanus sp. feeding on Coscinodiscus angstii, the decrease in chlorophyll… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)